CT shows effects of sarcopenia on liver cancer survival
CT has revealed that sarcopenia is a prognostic factor for poor overall survival after liver resection for cancer, researchers have reported. Five-year overall survival was significantly lower in sarcopenic patients than in those without the condition, at 58.2% and 83.6%, respectively, a team led by Thanatchawan Polvieng, MD, of Phramongkutklao Hospital in Bangkok, Thailand, reported. The results were published March 22 in American Surgeon. "Major postoperative complications were more frequent in sarcopenia," the group noted. Polvieng and colleagues conducted a study that explored the prognostic impact of sarcopenia (i....
Source: AuntMinnie.com Headlines - March 22, 2024 Category: Radiology Authors: Kate Madden Yee Tags: CT Abdominal Imaging Source Type: news

She beat a rare liver cancer – and now works with her father to find more cures
Cancer scientist decides to study the tumour that once afflicted his small daughter – and now her work is adding to his project’s successElana Simon was 10 years old when she started to experience severe pains in her abdomen. For two years, puzzled doctors put forward diagnoses including lactose intolerance, Crohn ’s disease and stress. It was not until 2008 that they pinpointed the real cause. Elana was suffering from fibrolamellar carcinoma(FLC), a rare, usually lethal, form of liver cancer.“In a way, it was comforting to have a word for what was wrong with me after so much confusion about my condition,” Elana ...
Source: Guardian Unlimited Science - March 16, 2024 Category: Science Authors: Robin McKie Science Editor Tags: Cancer research Medical research Science UK news Source Type: news

FAPI-PET/CT outperforms FDG-PET/CT in women with invasive breast cancer
This study underscores Ga-68 FAPI-PET/CT’s superiority over F-18 FDG-PET/CT for ILC,” the group concluded. A link to the full study can be found here. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: Will Morton Tags: Breast Source Type: news

ARRS announces Resident/Fellow in Radiology awardees
The American Roentgen Ray Society (ARRS) is recognizing four radiologists, as well as their institutions and research projects, with its 2024 ARRS Resident/Fellow in Radiology Awards. The following radiologists and their research projects are recognized as awardees: ul.editorialList li {margin-bottom:6px;} Melina Hosseiny, MD, University of California, San Diego. ARRS President’s Award for “Multi-task Ensemble Deep Learning for Differential Diagnosis of Pneumonia and Pulmonary Edema on Chest Radiograph.” Ahmed Taher, MD, University of Texas Health Science Center at Houston. ARRS Executive Council Award for “...
Source: AuntMinnie.com Headlines - March 12, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: People in the News Source Type: news

LR-M category tied to lower survival in HCC resection patients
Non-liver cancer-specific malignant lesions (LR-M) on CT or MRI are tied to lower overall survival in patients with solitary hepatocellular carcinoma (HCC) undergoing resection, a study published February 27 in Radiology found. Researchers led by Roberto Cannella, MD, from the University of Palermo in Italy also found that the presence of at least one non-targetoid feature is linked to increased recurrence risk, regardless of LI-RADS category. “Overall, our results confirm that the LR-M category should be considered in addition to pathology,” Cannella and colleagues wrote. The Liver Imaging Reporting and Data System...
Source: AuntMinnie.com Headlines - February 27, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: CT MRI Source Type: news

Machine Learning Helps Predict HCC Risk in MASLD Machine Learning Helps Predict HCC Risk in MASLD
A machine learning model can help estimate the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Gastroenterology Source Type: news

Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2024 Category: Pharmaceuticals Source Type: news

New Standard for Unresectable Hepatocellular Carcinoma?
(MedPage Today) -- SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed. Patients who received durvalumab... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 21, 2024 Category: Gastroenterology Source Type: news

Patient adherence to ultrasound liver cancer surveillance recs is low
Patient adherence to ultrasound hepatocellular carcinoma (HCC) surveillance imaging recommendations has been suboptimal, according to research published January 12 in Radiology: Imaging Cancer.Ultrasound is considered a cost-effective surveillance method in the management of HCC, a common type of liver cancer associated with long-term liver damage and scarring of the liver and chronic infections such as hepatitis B and hepatitis C, a research team from the University of California, San Francisco (UCSF) noted. But whether patients comply with surveillance recommendations prompted by the ultrasound LI-RADS metric isn't cle...
Source: AuntMinnie.com Headlines - January 16, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news

LI-RADS shows low NPV in per-patient liver tumor assessment
Per-patient grouping for liver tumor status based on LI-RADS and treatment response shows low negative predictive value (NPV) in detecting residual or untreated tumors, according to research published December 19 in Radiology.  A team led by Omar Hassan, MD, from the University of California, San Francisco studied hepatocellular carcinoma (HCC) patients who underwent local-regional therapy followed by liver transplant. The team found that per-patient stratification of tumor status at either pretransplant CT or MRI based on the LI-RADS version 2018 treatment response algorithm showed low NPV in this area. “The relativel...
Source: AuntMinnie.com Headlines - December 20, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: MRI Abdominal Imaging Source Type: news

Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial
(MedPage Today) -- Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an international phase III trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 14, 2023 Category: Gastroenterology Source Type: news

ABK Biomedical Announces That its Eye90 Microspheres(R) Device Has Been Granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)
HALIFAX, NS, Dec. 5, 2023 -- (Healthcare Sales & Marketing Network) - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 mi... Devices, Oncology, FDA ABK Biomedical, Eye90 microspheres, Hepatocellular Carcinoma, embolic therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2023 Category: Pharmaceuticals Source Type: news

STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice | Science Signaling
Liver tumor growth in mice is exacerbated by a feed-forward loop triggered by the palmitoylation of STAT3. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - December 5, 2023 Category: Science Source Type: news